10X Genomics Inc vs Zoom Video Communications, Inc. — how do they compare? 10X Genomics Inc trades at $56.91 (market cap $7.61B), while Zoom Video Communications, Inc. trades at $103.76 (market cap $31.10B). The key difference: Zoom Video Communications, Inc. is far larger — about 4.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals.
| TXG | ZM | |
|---|---|---|
Market Cap | $7.61B | $31.10B |
Sector | Health | Technology |
52-Week High | $58.57 | $111.88 |
52-Week Low | $11.34 | $69.96 |
Enterprise Value | $7.14B | $23.44B |
Signals from Pluang's Aura AI — not financial advice
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Zoom Communications (ZM) trades at $103.75, down 3.22% on the day, near the analyst consensus low price target of $104.00. The stock shows a bullish technical trend per moving averages, though oscillators indicate overbought conditions. Fundamentally, revenue grew to $4.67 billion in 2025 with a strong net income margin of 41.99%, while recent earnings beat expectations in Q1 2026. Analyst sentiment is mixed with a 38.78% buy rating, and insider selling has been notable in recent weeks.
The outlook for ZM hinges on continued execution amid competitive pressures. Upside exists if the company meets Q2 2026 EPS expectations of $1.48 and sustains high profitability, but risks include insider selling trends and potential growth deceleration. The stock's valuation at a P/E of 15.62 appears reasonable if earnings growth persists.
Trailing returns across standard periods
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →